Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CJ-30061 vs Exforge + Lipitor in Healthy Volunteers
NCT03657472Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Sep 2016
- Primary completion
- Oct 2016
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Exone-A in hypertension (HTN) and hyperlipidemia (3 arms), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration of Amlodipine up to 72 hours, Maximum Plasma Concentration of Valsartan up to 72 hours and 4 more. Started Sep 2016; status: completed.
02
Drugs
Exone-A
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT03657472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657472.